Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, RESEARCH & TRANSL SCIENCE | November 19, 2021 | November 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date November 19, 2021 · Filed November 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 330,752 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Tax withholding · Disposed 4,310 · Balance 330,752 F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2021 Filed Nov 23, 2021 20:21 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,310 | $8.36 | $36,031.60 |
DisclosureSEC source: 0001415889-21-005465 · form4-11232021_051137.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, RESEARCH & TRANSL SCIENCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,752 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 19:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,307 | $14.05 | $60,513.35 |
DisclosureSEC source: 0001179110-21-008406 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,062 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2021 Filed May 24, 2021 18:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,310 | $17.80 | $76,718.00 |
DisclosureSEC source: 0001179110-21-005854 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,369 Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 19:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 8,829 | $20.00 | $176,580.00 |
DisclosureSEC source: 0001179110-21-003282 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,679 Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 18:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 31,887 | $18.79 | $599,156.73 |
DisclosureSEC source: 0001179110-21-002178 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,508 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:55 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001542 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,395 Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 18:42 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 4,246 | $18.00 | $76,428.00 |
DisclosureSEC source: 0001179110-20-011737 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,395 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,807 | $17.21 | $82,728.47 |
DisclosureSEC source: 0001179110-20-011379 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,641 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:38 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,804 | $18.22 | $87,528.88 |
DisclosureSEC source: 0001179110-20-009277 · edgar.xml · nonDerivative · entry 2 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,448 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:38 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 17,103 | $18.00 | $307,854.00 |
DisclosureSEC source: 0001179110-20-009277 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,252 Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,807 | $26.67 | $128,202.69 |
DisclosureSEC source: 0001179110-20-006538 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,355 F1 · balance_after: Includes 412 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 29,105 | $25.90 | $753,819.50 |
DisclosureSEC source: 0001179110-20-002158 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,750 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 19:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001212 · edgar.xml · nonDerivative · entry 2 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,855 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 3, 2020, the performance conditions applicable to 54,000 shares were achieved and such shares will vest on February 20, 2021, subject to the reporting person's continued service. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 19:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001212 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,855 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 18:28 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $17.60 | $39,987.20 |
DisclosureSEC source: 0001179110-19-012025 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,855 Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 18:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $21.51 | $48,870.72 |
DisclosureSEC source: 0001179110-19-009800 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,127 Read SEC document |
| May 20, 2019 Filed May 22, 2019 18:19 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $19.84 | $45,076.48 |
DisclosureSEC source: 0001179110-19-006541 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,399 F1 · balance_after: Includes 1,027 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2019. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 18:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,986 | $27.00 | $107,622.00 |
DisclosureSEC source: 0001179110-19-002435 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,644 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:51 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001574 · edgar.xml · nonDerivative · entry 2 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,630 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:51 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001574 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,380 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:48 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,373 | $24.79 | $108,406.67 |
DisclosureSEC source: 0001179110-18-013112 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,380 Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 17:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 6,393 | $28.50 | $182,200.50 |
DisclosureSEC source: 0001179110-18-011431 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,753 Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 19:35 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,508 | $26.95 | $148,440.60 |
DisclosureSEC source: 0001179110-18-010824 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,146 Read SEC document |
| May 20, 2018 Filed May 22, 2018 19:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 19,524 | $24.31 | $474,628.44 |
DisclosureSEC source: 0001179110-18-007377 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,654 Read SEC document |
| May 14, 2018 Filed May 16, 2018 19:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006941 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,178 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018. F2 · balance_after: Includes 865 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:42 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,566 | $29.09 | $132,824.94 |
DisclosureSEC source: 0001179110-18-002615 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,563 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 18:24 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002132 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,129 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 16:40 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,503 | $28.58 | $157,275.74 |
DisclosureSEC source: 0001179110-17-014567 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,129 Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 18:31 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,502 | $27.40 | $150,754.80 |
DisclosureSEC source: 0001179110-17-011752 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,632 Read SEC document |
| May 20, 2017 Filed May 23, 2017 20:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,503 | $36.83 | $202,675.49 |
DisclosureSEC source: 0001179110-17-007883 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,134 F1 · balance_after: Includes 1,702 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2017. Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 19:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 10,397 | $33.78 | $351,210.66 |
DisclosureSEC source: 0001179110-17-002996 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,935 Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 19:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002004 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,332 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 18:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,104 | $31.96 | $67,243.84 |
DisclosureSEC source: 0001179110-16-031983 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Translational Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,332 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.